Research Analysts Offer Predictions for DFTX FY2026 Earnings

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Stock analysts at Lifesci Capital cut their FY2026 earnings per share estimates for Definium Therapeutics in a report released on Friday, June 5th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings of ($2.32) per share for the year, down from their prior estimate of ($2.31). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.30) per share.

A number of other brokerages have also recently weighed in on DFTX. Leerink Partners lifted their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Oppenheimer reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Definium Therapeutics in a research note on Thursday, April 23rd. Piper Sandler reissued an “overweight” rating and set a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. HC Wainwright boosted their target price on Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Canaccord Genuity Group set a $38.00 target price on Definium Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 16th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $37.92.

Definium Therapeutics Trading Down 2.3%

Shares of NASDAQ DFTX opened at $23.02 on Tuesday. Definium Therapeutics has a twelve month low of $6.34 and a twelve month high of $26.25. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $21.92 and a 200-day simple moving average of $17.62. The stock has a market capitalization of $2.30 billion, a PE ratio of -9.24 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. BIT Capital GmbH acquired a new position in Definium Therapeutics during the 3rd quarter worth $26,000. Fifth Third Bancorp lifted its holdings in Definium Therapeutics by 5,593.2% during the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after buying an additional 3,300 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares during the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new stake in Definium Therapeutics during the 4th quarter worth about $117,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.